Aeterna Zentaris Inc - Company Profile
Powered by 
All the data and insights you need on Aeterna Zentaris Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Aeterna Zentaris Inc Strategy Report
- Understand Aeterna Zentaris Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Aeterna Zentaris Inc (Aeterna Zentaris) is a specialty biopharmaceutical company that focuses on the development and commercialization of novel pharmaceutical therapies for the treatment of unmet medical needs. The company’s lead product, Macrilen (macimorelin), a ghrelin receptor agonist and the orally active small molecule is used for the treatment of patients with adult growth hormone deficiency (AGHD). The company has operations in the US, Canada, and Germany and has license agreements for its products in Ireland, China, the British Virgin Islands, Denmark and other countries. Aeterna Zentaris is headquartered in Summerville, South Carolina, the US.
Headquarters
Canada
Address
315 Sigma Drive, Summerville, New Brunswick, 29486
Website
www.zentaris.com
Telephone
1 418 6528525
No of Employees
21
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
AEZS (TSE)
Revenue (2022)
$4.5M
-20.2%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
27.2%
(2022 vs 2021)
Market Cap*
$9.5M
Net Profit Margin (2022)
XYZ
8.7%
(2022 vs 2021)
* As of and is in US$
Aeterna Zentaris Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Macrilen - Adult Growth Hormone Deficiency |
| Pipeline |
| Macrilen- child-onset growth hormone deficiency |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In March, the company received approval from the Court of King's Bench of Alberta to merge with Ceapro. |
| 2023 | Contracts/Agreements | In December, the company entered into an agreement to merge with Ceapro Inc. |
| 2021 | Contracts/Agreements | In February, the company signed an agreement with the Julius-Maximilians-University to analyse the latter’s preclinical potential Covid-19 vaccine. |
Competitor Comparison
| Key Parameters | Aeterna Zentaris Inc | Pfizer Inc | Eli Lilly and Co | Theratechnologies Inc | Lumos Pharma Inc |
|---|---|---|---|---|---|
| Headquarters | Canada | United States of America | United States of America | Canada | United States of America |
| City | Summerville | New York | Indianapolis | Montreal | Austin |
| State/Province | New Brunswick | New York | Indiana | Quebec | Texas |
| No. of Employees | 21 | 88,000 | 43,000 | 89 | 33 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Carolyn Egbert | Chairman | Executive Board | 2016 | - |
| Klaus Paulini | Director; President; Chief Executive Officer | Executive Board | 2019 | - |
| Giuliano La Fratta | Senior Vice President; Chief Financial Officer | Senior Management | 2021 | - |
| Nicola Ammer, M.D | Chief Medical Officer; Senior Vice President; Head - Clinical Development, Aeterna Zentaris GmbH | Senior Management | 2018 | - |
| Michael Teifel, PhD | Senior Vice President - Non-Clinical Development; Chief Scientific Officer | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer